Brief Summary
The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.
Protocol Interventions
Drug: Treatment Plan 2: Strata 2, 3, or 4, Drug: GVHD Regimen A: UCB Recipients, Drug: GVHD Regimen B: BM Recipients